These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16243890)

  • 41. The clinical challenge of infections due to Pseudomonas aeruginosa.
    Young LS
    Rev Infect Dis; 1984; 6 Suppl 3():S603-7. PubMed ID: 6443761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidemiological investigation and glycotyping of clinical Pseudomonas aeruginosa isolates from patients with cystic fibrosis by mass spectrometry: association with multiple drug resistance.
    Altman E; Wang Z; Aaron SD; Liu X; Vandemheen KL; Ferris W; Giesbrecht T; Li J
    J Microbiol Methods; 2009 Feb; 76(2):204-8. PubMed ID: 19000720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic review of nebulized antibiotics in cystic fibrosis: evolution of protocol.
    Mukhopadhyay S; Singh M; Ogston S; Ryan G; Smyth R
    J R Soc Med; 1998; 91 Suppl 34(Suppl 34):25-9. PubMed ID: 9709385
    [No Abstract]   [Full Text] [Related]  

  • 45. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
    Lapointe JR; Bourget C; Mainville S; Lafleur L; Lagacé J; Montplaisir S
    J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360
    [No Abstract]   [Full Text] [Related]  

  • 46. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis.
    Hoekstra MO; van Aalderen WM
    Thorax; 1997 Apr; 52(4):398-9. PubMed ID: 9196534
    [No Abstract]   [Full Text] [Related]  

  • 47. Optimizing antipseudomonal therapy in critical care.
    Iredell JR
    Semin Respir Crit Care Med; 2007 Dec; 28(6):656-61. PubMed ID: 18095229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term home-based parenteral antibiotic treatment of a prosthetic vascular graft infection caused by Pseudomonas aeruginosa.
    Terpling S; Schade Larsen C; Schønheyder HC
    Scand J Infect Dis; 2006; 38(5):388-92. PubMed ID: 16709546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Treggiari MM; Rosenfeld M; Retsch-Bogart G; Gibson R; Ramsey B
    Pediatr Pulmonol; 2007 Sep; 42(9):751-6. PubMed ID: 17647287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
    Bradbury R; Champion A; Reid DW
    Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Refractory respiratory tract infections. 4. Selection of chemotherapeutic agents and their administration. c. Pseudomonas infections].
    Oizumi K
    Nihon Rinsho; 1987 Mar; 45(3):526-30. PubMed ID: 3298728
    [No Abstract]   [Full Text] [Related]  

  • 52. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
    De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M
    J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Respiratory infections by Pseudomonas aeruginosa in the elderly].
    Yamamoto K; Yamada Y; Nakamura A; Takeuchi T
    Nihon Rinsho; 1991 Oct; 49(10):2317-22. PubMed ID: 1749088
    [No Abstract]   [Full Text] [Related]  

  • 54. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis.
    McNamara PS; McCormack P; McDonald AJ; Heaf L; Southern KW
    J Cyst Fibros; 2009 Jul; 8(4):258-63. PubMed ID: 19447080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pseudomonas infections in cystic fibrosis.
    George RH
    Arch Dis Child; 1987 May; 62(5):438-9. PubMed ID: 3111389
    [No Abstract]   [Full Text] [Related]  

  • 56. [Pseudomonas aeruginosa pneumonia].
    Watanabe K
    Nihon Rinsho; 1991 Oct; 49(10):2306-11. PubMed ID: 1749086
    [No Abstract]   [Full Text] [Related]  

  • 57. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
    Wolter DJ; Black JA; Lister PD; Hanson ND
    J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cystic fibrosis: current therapy. Antibiotics].
    Tamm M; Héritier F; Rappaz I; Schaad UB
    Schweiz Med Wochenschr Suppl; 2000; 122():33S-37S. PubMed ID: 12536469
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of Pseudomona aeruginosa infections].
    Hornowski S; Olkowski L; Dzwonkowski S
    Wiad Lek; 1968 Feb; 21(3):181-4. PubMed ID: 4970022
    [No Abstract]   [Full Text] [Related]  

  • 60. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
    Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
    Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.